Clinical Trials Directory

Trials / Unknown

UnknownNCT03929965

Anlotinib in Advanced Solid Tumors With FGFR Alteration

Status
Unknown
Phase
N/A
Study type
Interventional
Enrollment
30 (estimated)
Sponsor
Shanghai Changzheng Hospital · Academic / Other
Sex
All
Age
18 Years – 75 Years
Healthy volunteers
Not accepted

Summary

This clinical trial aims to evaluate the efficacy, safety of Anlotinib in advanced solid tumors with FGFR alteration.

Conditions

Interventions

TypeNameDescription
DRUGAnlotinibAnlotinib

Timeline

Start date
2019-07-01
Primary completion
2020-07-01
Completion
2023-07-01
First posted
2019-04-29
Last updated
2019-04-29

Locations

3 sites across 1 country: China

Source: ClinicalTrials.gov record NCT03929965. Inclusion in this directory is not an endorsement.